Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with this BCL-2 antagonist has revealed emergence of a drug-selected BCL-2 mutation (G101V) in some patients failing t...

Full description

Saved in:
Bibliographic Details
Published in:Nat Commun
Main Authors: Birkinshaw, Richard W., Gong, Jia-nan, Luo, Cindy S., Lio, Daisy, White, Christine A., Anderson, Mary Ann, Blombery, Piers, Lessene, Guillaume, Majewski, Ian J., Thijssen, Rachel, Roberts, Andrew W., Huang, David C. S., Colman, Peter M., Czabotar, Peter E.
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6547681/
https://ncbi.nlm.nih.gov/pubmed/31160589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-10363-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items